Global independent biotech leader Amgen (Nasdaq: AMGN) reported fourth-quarter 2011 results with 3% growth in revenues to $3.97 billion, Adjusted net income decreased 6% to $1.04 million, or adjusted earnings per share of $1.21 (+3%). Reported net income fell 9% to $934 million, or $1.08 per share.
For the full year, Amgen said that net income fell 20% to $3.7 billion on revenues of $15.6 billion, a year-on-year rise of 4%. The company noted that the lower profits reflect a previously disclosed change for a legal settlement. Analysts’ consensus expectations were for adjusted income of $5.33 per share on average and revenue of $15.5 billion.
The company, which the same day announced a proposed $1.16 billion acquisition of biotech firm Micromet (The Pharma Letter January 27), expects full-year 2012 total revenues in the range of $16.1 to $16.5 billion; and adjusted EPS of $5.90 to $6.15; adjusted tax rate of 14% to 15%. This was in line with analysts’ estimates of EPS at $5.94 on sales of $16.1 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze